<DOC>
	<DOCNO>NCT01782261</DOCNO>
	<brief_summary>Assessment effect incretin base therapy ( Liraglutide Saxagliptin ) immune cell healthy subject patient type 1 diabetes</brief_summary>
	<brief_title>Incretin Effect Immunological Phenotype</brief_title>
	<detailed_description>Assessment immunological effect Saxagliptin Liraglutide immune cell peripheral blood .</detailed_description>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>healthy subject patient type 1 diabetes pregnancy treatment GLP1Analoga ( Liraglutide , Exenatide ) treatment DPP4inhibitor ( Sitagliptin , Vildagliptin , Saxagliptin ) chronic disease include longterm medication 4 week per year ( except type 1 diabetes )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>autoimmune disease</keyword>
	<keyword>diabetes type 1</keyword>
	<keyword>incretin effect</keyword>
</DOC>